Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis

BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment is delayed disease progression. The degree to which early therapeutic success affects downstream outcomes is not well established. OBJECTIVE: To assess the clinical and economic impact of early vs delayed disease...

Descripción completa

Detalles Bibliográficos
Autores principales: Hutson, Thomas E, Liu, Frank X, Dieyi, Christopher, Kim, Ruth, Krulewicz, Stan, Kasturi, Vijay, Bhanegaonkar, Abhijeet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394198/
https://www.ncbi.nlm.nih.gov/pubmed/34165322
http://dx.doi.org/10.18553/jmcp.2021.20569

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394198/
https://www.ncbi.nlm.nih.gov/pubmed/34165322
http://dx.doi.org/10.18553/jmcp.2021.20569

Ejemplares similares